Project

A first-in-human, open-label, multicenter Phase l/ll study to evaluate the safety and anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1)

Ongoing - recruitment active · 2024 until 2028

Jörger Markus, Sennhauser Andrina, Müller Fiona